Does DPP-IV Inhibition Offer New Avenues for Therapeutic Intervention in Malignant Disease?
Dipeptidyl peptidase IV (DPP-IV, CD26) is frequently dysregulated in cancer and plays an important role in regulating multiple bioactive peptides with the potential to influence cancer progression and the recruitment of immune cells. Therefore, it represents a potential contributing factor to cancer...
Main Authors: | Petr Busek, Jonathan S. Duke-Cohan, Aleksi Sedo |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2022-04-01
|
Series: | Cancers |
Subjects: | |
Online Access: | https://www.mdpi.com/2072-6694/14/9/2072 |
Similar Items
-
Sitagliptin: the world’s first DPP-4 inhibitor
by: N. A. Petunina, et al.
Published: (2019-08-01) -
Is there a Chance to Promote Arteriogenesis by DPP4 Inhibitors Even in Type 2 Diabetes? A Critical Review
by: Srinivasan Vedantham, et al.
Published: (2018-10-01) -
3D-QSAR-based pharmacophore determination and design of novel DPP-4 inhibitors
by: Rogić Sanja, et al.
Published: (2022-01-01) -
National Council of Experts: the place of DPP-4 inhibitors in the treatment of patients with type 2 diabetes mellitus
by: M. V. Shestakova, et al.
Published: (2023-12-01) -
Repurposing DPP-4 Inhibitors for Colorectal Cancer: A Retrospective and Single Center Study
by: Lui Ng, et al.
Published: (2021-07-01)